Gilead beats Q3 2026 earnings, lifts full‑year sales outlook on strong HIV growth
Gilead Sciences reported third‑quarter 2026 product sales of $8.3 billion, topping analysts’ forecasts, and non‑GAAP diluted EPS of $2.55. HIV sales rose 18% to $6.2 billion, driven by Biktarvy and PrEP products, while base‑business sales grew 16% to $8.2 billion. The company raised its FY‑2026 total sales guidance to $31.0‑$31.3 billion and widened its non‑GAAP loss range, while warning that Medicare pricing will cut Biktarvy revenue by about $1.5 billion in 2028.
Why it matters
The higher guidance signals stronger near‑term revenue and cash flow, supporting the current stock price (Investing.com notes a price‑target lift). However, the disclosed $1.5 billion 2028 pricing hit creates a future earnings head‑wind that investors must factor into valuation models (BigGo Finance’s call notes the impact).
Key facts
- 1Total product sales were $8.3 billion, up 13% year‑over‑year. stocktitan.net
- 2Non‑GAAP diluted EPS was $2.55, beating consensus. finance.biggo.com
- 3Base‑business sales reached $8.2 billion, a 16% year‑over‑year increase. finance.biggo.com
- 4HIV sales totaled $6.2 billion, up 18% year‑over‑year. finance.biggo.com
- 5FY‑2026 total sales guidance was raised to $31.0‑$31.3 billion. finance.biggo.com
- 6The company expects Medicare pricing to reduce Biktarvy revenue by roughly $1.5 billion in 2028. tradingview.com
Summary written by AlphAI AI Desk from 20 of 26 sources. Not investment advice. Figures are as stated by the linked sources.